Lack of β adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine

European Neuropsychopharmacology

Volumn 8, Issue 3, 1998, Pages 227-232

  Nalepa, Irena ^a   Manier, D Hal ^b   Gillespie, David D ^b   Rossby, S Paul ^b   Schmidt, Dennis E ^b   Sulser, Fridolin ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta adrenoceptors; Cyclic AMP responses; Noradrenaline; Serotonin; Venlafaxine

Indexed keywords

ADENYLATE CYCLASE; BETA ADRENERGIC RECEPTOR; CYCLIC AMP; DESIPRAMINE; NORADRENALIN; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SECOND MESSENGER; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; BRAIN; BRAIN CHEMISTRY; CYCLIC AMP; CYCLOHEXANOLS; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0032145462     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00078-3     Document Type: Article

References (32)

1. Arriza J.L., Dawson T.M., Limerly R.B., Martin L.J., Carm M.G., Snyder S.H., Lefkowitz R.J. The G-protein-coupled receptor kinase βARK1 and βARK2 are widely distributed at synapses in rat brain. J. Neurosci. 12:1992;4045-4055.
2. Assie, M.B., Broadhurst, A., Briley, M., 1988. Is down-regulation of β-adrenoceptors necessary for antidepressant activity? In: Briley, M., Fillion, G. (Eds.), New Concepts in Depression. MacMillan Press, London, pp. 161-166.
3. Banerjee S.P., Kung L.S., Riggi S.J., Chanda S.K. Development of β adrenergic receptor subsensitivity by antidepressants. Nature. 268:1976;455-456.
4. Benovic J.L., Bouvier W., Caron M.W.G., Lefkowitz R.J. Regulation of adenylate cyclase-coupled β-adrenergic receptors. Annu. Rev. Cell. Biol. 4:1988;405-428.
5. Berridge, M.J., 1986. Inositol trisphosphate: a new second messenger. In: Filon, J.C., Geisler, A., Norm, S. (Eds.), Drug Receptors and Dynamic Processes in Cells. Munksgard, Copenhagen, pp. 90-102.
6. Bolden-Watson C., Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
7. Briley M., Moret C.H. Neurobiological mechanisms involved in antidepressant therapies. Clin. Neuropharmacol. 16:1993;387-400.
8. Bylund D.B., Snyder S.H. B adrenergic receptor binding in membrane preparations from mammalian brain. Mol. Pharmacol. 12:1976;568-580.
9. Eiring A., Manier D.H., Bieck P.R., Howells R.D., Sulser F. The Serotonin/Noradrenaline/Link beyond the β adrenoceptors. Mol. Brain Res. 16:1992;211-214.
10. Gillespie D.D., Manier D.H., Sanders-Bush E., Sulser F. The serotonin/noradrenaline link in brain: II. The role of serotonin in the regulation of β-adrenoceptors in the low agonist affinity conformation. J. Pharmacol. Exp. Ther. 244:1988;154-159.
11. Hoeffler J.P., Deutsch P.J., Lin J., Habenes L.F. Cyclic adenosine monophosphate and phorbol esters - responsive signal transduction pathways converge at the level of transcriptional activation by the interactions of DNA-binding proteins. Mol. Endocrinol. 3:1989;868-880.
12. Lowry D.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
13. Manier D.H., Gillespie D.D., Sulser F. 5,7-Dihydroxytryptamine induced lesions of serotonergic neurons and desipramine induced down-regulation of cortical β adrenoceptors: a re-evaluation. Biochem. Pharmacol. 36:1987;3308-3310.
14. Moret C., Charveron M., Finberg J.P.M., Couzinier J.P., Briley M. Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethylaminocarbonyl-2-amino methyl cyclopropane (z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 24:1985;1211-1219.
15. Moyer J.A., Muth E.A., Haskins J.T., Lappe R.W., Sigg E.B. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45030 and Wy-45881. Soc. Neurosci. 10:1984;26.
16. Muth E.A., Moyer J.A., Haskins J.T., Andree T.H., Husbands G.E. Biochemical, neuropathophysiological and behavioral effects of Wy-45233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23:1991;191-199.
17. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., Nielsen S.T., Sigg E.B. Antidepressant biochemical profile of the mood tricyclic compound Wy-45030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35:1986;4493-4497.
18. Nalepa I., Vetulani J. Enhancement of the responsiveness of cortical adrenergic receptors by chronic administration of the 5-hydroxytryptamine uptake inhibitor citalopram. J. Neurochem. 60:1993;2029-2035.
19. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of CREB in rat hippocampus. J. Neurosci. 16:1996;2365-2372.
20. Premont R.T., Inglese J., Lefkowitz R.J. Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J. 9:1995;175-182.
21. Pryor, J.C., Sulser, F., 1991. Evolution of monoamine hypotheses of depression. In: Horton, R.W., Katona, C. (Eds.), Biological Aspects of Affective Disorders. Academic Press, London, pp. 77-94.
22. Rossby S.P., Perrin C., Burt A., Nalepa I., Schmidt D.E., Sulser F. Fluoxetine increases steady-state levels of preproenkephalin mRNA in rat amygdala by a serotonin dependent mechanism. J. Serotonin Res. 3:1996;69-74.
23. Schmidt D.E., Roznoski M.L., Ebert M.H. Qualitative and quantitative HPLC analysis of monoamine neurotransmitters and metabolites in CSF and brain tissue using reductive electrochemical detection. Biomed. Chromatogr. 4:1990;215-218.
24. Sellinger M.D., Mendels J., Frazer A. The effect of psychoactive drugs on β-adrenergic receptor binding sites in rat brain. Neuropharmacology. 19:1980;447-454.
25. Shih M., Malbon C.C. Oligodeoxynucleotides antisense to mRNA encoding protein kinase A, protein kinase C and β-adrenergic receptor kinase reveal distinctive cell-type specific roles in agonist-induced desensitization. Proc. Natl. Acad. Sci. USA. 91:1994;12193-12197.
26. Sulser F. New perspectives on the molecular pharmacology of affective disorders. Eur. Arch. Psychiatry Neurol. Sci. 238:1989;231-237.
27. Sulser, F., Sanders-Bush, E., 1989. The serotonin/noradrenaline steroid receptor link in brain and the mode of action of antidepressants. In: Lerer, B., Gershon, S. (Eds.), New Directions in Affective Disorders. Springer-Verlag, New York, pp. 85-88.
28. Vetulani J., Sulser F. Action of various antidepressant treatment reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain. Nature. 257:1975;495-496.
29. Wong D.T., Bymaster F.P., Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 57:1995;411-441.
30. Wurtman, R.J., Axelrod, J., Kelly, D.E., 1968. The Pineal. Academic Press, New York.
31. Yardley J.P., Husbands G.E.M., Stock G., Butch J., Bicksler J., Moyer J.A., Muth E.A., Andree T., Fletcher H., James M.N.G., Sielecki A.R. 2-Phenyl-2-(1-hydroxy cycloalkyl) ethylamine derivatives: synthesis and antidepressant activity. J. Med. Chem. 33:1990;2899-2905.
32. Yoshikawa K., Sabol S. Expression of the enkephalin precursor gene in C6 rat glioma cells: regulation by β adrenergic agonists and glucocorticoids. Mol. Brain Res. 1:1986;75-83.